This effect on bone mineral markers has been associated with FCM use and is often termed 6‐H syndrome, inclusive of high FGF23, hyperphosphaturia, HPP, hypovitaminosis D, hypocalcemia, and secondary hyperparathyroidism [10, 23, 24, 25]. Here, FGF23 is linked to Hypocalcemia.